Sakamoto R - Search Results

1

Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.

Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, Sakamoto R. Nakamura T, et al. Among authors: sakamoto r. Eur J Pharmacol. 2016 Jun 5;780:224-31. doi: 10.1016/j.ejphar.2016.03.055. Epub 2016 Mar 30. Eur J Pharmacol. 2016. PMID: 27038523

2

Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin.

Zhang Y, Fukusumi Y, Kayaba M, Nakamura T, Sakamoto R, Ashizawa N, Kawachi H. Zhang Y, et al. Among authors: sakamoto r. Nefrologia (Engl Ed). 2021 Sep-Oct;41(5):539-547. doi: 10.1016/j.nefroe.2021.11.007. Nefrologia (Engl Ed). 2021. PMID: 36165136 Free article.

3

[No title available]

[No authors listed] [No authors listed] PMID: 33707098

4

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, Okui D, Kimura K. Wada T, et al. Among authors: sakamoto r. Clin Exp Nephrol. 2018 Aug;22(4):860-870. doi: 10.1007/s10157-018-1530-1. Epub 2018 Jan 25. Clin Exp Nephrol. 2018. PMID: 29372470 Clinical Trial.

5

Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.

Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T. Hosoya T, et al. Among authors: sakamoto r. J Clin Pharm Ther. 2016 Jun;41(3):298-305. doi: 10.1111/jcpt.12392. Epub 2016 Apr 15. J Clin Pharm Ther. 2016. PMID: 27079434 Clinical Trial.

6

Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.

Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Hosoya T, et al. Among authors: sakamoto r. J Clin Pharm Ther. 2016 Jun;41(3):290-7. doi: 10.1111/jcpt.12391. Epub 2016 Apr 24. J Clin Pharm Ther. 2016. PMID: 27109450 Clinical Trial.

7

Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.

Hosoya T, Ishikawa T, Ogawa Y, Sakamoto R, Ohashi T. Hosoya T, et al. Among authors: sakamoto r. Clin Drug Investig. 2018 Dec;38(12):1135-1143. doi: 10.1007/s40261-018-0699-0. Clin Drug Investig. 2018. PMID: 30219951 Free PMC article. Clinical Trial.

8

An Autopsied Case of Erdheim-Chester Disease with Severe Cardiovascular Involvement.

Matsunashi A, Zhipeng W, Sugimoto A, Fujimoto M, Yoshizawa A, Sakamoto R, Uyama M, Ikezoe K, Tanizawa K, Handa T, Hirai T. Matsunashi A, et al. Among authors: sakamoto r. Intern Med. 2024 Nov 28. doi: 10.2169/internalmedicine.4247-24. Online ahead of print. Intern Med. 2024. PMID: 39603629 Free article.

9

Mechanical power is maximized during contractile ring-like formation in a biomimetic dividing cell model.

Sakamoto R, Murrell MP. Sakamoto R, et al. Nat Commun. 2024 Nov 10;15(1):9731. doi: 10.1038/s41467-024-53228-y. Nat Commun. 2024. PMID: 39523366 Free PMC article.

10

Synergistic Interplay between Fe-Based Perovskite Oxides and Co in Electrolyte for Efficient Oxygen Evolution Reaction.

Inoue Y, Miyahara Y, Miyazaki K, Lee C, Sakamoto R, Abe T. Inoue Y, et al. Among authors: sakamoto r. ChemSusChem. 2024 Nov 11:e202401982. doi: 10.1002/cssc.202401982. Online ahead of print. ChemSusChem. 2024. PMID: 39526780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

734 results

Search Page

Filters